Literature DB >> 17938277

Clinicopathologic factors and nuclear morphometry as independent prognosticators in KIT-positive gastrointestinal stromal tumors.

Sonja E Steigen1, Bjørn Straume, Dmitry Turbin, Andy K W Chan, Samuel Leung, Torsten O Nielsen, Sigurd Lindal.   

Abstract

Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms found in the gastrointestinal tract. The purpose of this study was to evaluate whether morphometric measurements could complement tumor size and mitotic activity in risk evaluation. Nuclear roundness and ellipse axis ratio were found to correlate with tumor size, mitotic activity, nuclear atypia, and hemorrhage. Morphometric variables in 422 GISTs were significant for overall survival in univariate analyses but did not retain independent significance in multivariate analyses incorporating mitotic count and tumor size. Traditional variables, together with sex, location of primary tumor, and nuclear atypia, seem to be the best parameters for prognostic evaluation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938277      PMCID: PMC2324167          DOI: 10.1369/jhc.7A7333.2007

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  24 in total

1.  Correlation of nuclear morphometry with pathologic parameters in ductal carcinoma in situ of the breast.

Authors:  P H Tan; B B Goh; G Chiang; B H Bay
Journal:  Mod Pathol       Date:  2001-10       Impact factor: 7.842

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast.

Authors:  A Hoque; S M Lippman; I V Boiko; E N Atkinson; N Sneige; A Sahin; D M Weber; S Risin; M D Lagios; R Schwarting; W J Colburn; K Dhingra; M Follen; G J Kelloff; C W Boone; W N Hittelman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-03       Impact factor: 4.254

4.  Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation.

Authors:  M Debiec-Rychter; J Lasota; M Sarlomo-Rikala; R Kordek; M Miettinen
Journal:  Cancer Genet Cytogenet       Date:  2001-07-01

5.  Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias.

Authors:  J P Baak; A Ørbo; P J van Diest; M Jiwa; P de Bruin; M Broeckaert; W Snijders; P J Boodt; G Fons; C Burger; R H Verheijen; P W Houben; H S The; P Kenemans
Journal:  Am J Surg Pathol       Date:  2001-07       Impact factor: 6.394

6.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Authors:  A T van Oosterom; I Judson; J Verweij; S Stroobants; E Donato di Paola; S Dimitrijevic; M Martens; A Webb; R Sciot; M Van Glabbeke; S Silberman; O S Nielsen
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

7.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray.

Authors:  Robin L Parker; David G Huntsman; David W Lesack; James B Cupples; Dennis R Grant; Majid Akbari; C Blake Gilks
Journal:  Am J Clin Pathol       Date:  2002-05       Impact factor: 2.493

Review 8.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Nuclear morphometric analysis in gastrointestinal stromal tumors: a preliminary study.

Authors:  Sükrü Oğuz Ozdamar; Sibel Bektaş; Sevim Erdem Ozdamar; Gökhan Gedikoğlu; Banu Doğan Gün; Burak Bahadir
Journal:  Turk J Gastroenterol       Date:  2007-06       Impact factor: 1.852

View more
  4 in total

1.  NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.

Authors:  Makoto Endo; Marieke A de Graaff; Davis R Ingram; Simin Lim; Dina C Lev; Inge H Briaire-de Bruijn; Neeta Somaiah; Judith V M G Bovée; Alexander J Lazar; Torsten O Nielsen
Journal:  Mod Pathol       Date:  2014-11-21       Impact factor: 7.842

2.  Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.

Authors:  Mayanne M T Zhu; Samantha Burugu; Dongxia Gao; Jamie Yu; Zuzana Kos; Samuel Leung; Basil A Horst; Torsten O Nielsen
Journal:  Mod Pathol       Date:  2020-04-29       Impact factor: 7.842

3.  Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages.

Authors:  Sean P Arlauckas; Seth B Garren; Chris S Garris; Rainer H Kohler; Juhyun Oh; Mikael J Pittet; Ralph Weissleder
Journal:  Theranostics       Date:  2018-11-12       Impact factor: 11.556

4.  Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.

Authors:  Amanda R Dancsok; Dongxia Gao; Anna F Lee; Sonja Eriksson Steigen; Jean-Yves Blay; David M Thomas; Robert G Maki; Torsten O Nielsen; Elizabeth G Demicco
Journal:  Oncoimmunology       Date:  2020-04-12       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.